Lu Dai, PA-C

Lu Dai practices at The University of Texas MD Anderson Cancer Center in Houston, Texas, part of The University of Texas System.

Lu Dai's NPI, 1790399731, was assigned on September 8, 2020. Lu Dai holds Texas license PA17569.

Lu Dai's primary practice is The University of Texas MD Anderson Cancer Center, at 1515 Holcombe Blvd, Houston, TX 77030.

Lu Dai's primary practice is The University of Texas MD Anderson Cancer Center in Houston, Texas, part of The University of Texas System. The medical group on file is University Hospitals Medical Practices. Dmand AI also links Lu Dai to 1 more group practice or clinic and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Lu Dai practices, 2 sites in all. Vendor and product names are available with a free account.

Physician assistant is Lu Dai's primary specialty in the NPI Registry, under taxonomy code 363A00000X. Lu Dai is licensed in Texas.

Dmand AI lists chronic kidney disease and vitamin b deficiency among the conditions Lu Dai treats.

CMS data shows 122 Medicare services from Lu Dai across 4 procedure codes in 2024, for 129 Medicare patients. Medicare paid $6,331 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 129 Medicare patients who saw Lu Dai in 2024. The largest group is 65 to 74, with 67 patients. 75% of them have high blood pressure, and 75% have high cholesterol. Their average risk score is 2.30, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Lu Dai's median patient age at 72, with 49% women.

In 2024, Lu Dai wrote 153 Medicare Part D claims for 64 patients. 92% of them were for generic drugs. CMS names the drug for 80 of them, across 3 drugs with 11 or more claims each, at $1,111 in total drug cost.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 84 out of 100 for Lu Dai for performance year 2024, reported as part of a group. Lu Dai accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Lu Dai as offering telehealth.

CMS Open Payments shows 9 general payments to Lu Dai from 7 drug and device companies from 2024 to 2025. Food and beverage make up the largest share, 76% of the total. Regeneron Pharmaceuticals, Inc. paid the most, $116.